

Review of: "On the Need for Better Information from Randomized Clinical Trials in Oncology"

Daniel Taussky¹

¹ Université de Montréal

Potential competing interests: Tolmar, Canada

This is more a pamphlet than a scientific article. It is polemic but refreshingly different and thought-provoking. You need to state the research question more precisely than just "To assess how RCT results in oncology are presented in the academic literature." This would help to be able to follow your train of thought before reaching the discussion.

I suggest that you add the following points in your discussion to concentrate not too much on the statistical discussion, because you ask if it matters for the patient.

You don't even mention the cost of using new drugs with no or very small AR.

You could discuss how PFS is defined, often only radiologically, and if radiological PFS is a valid endpoint.

We also have to weigh the increased rate of serious side effects (AE grade 3-5) versus the statistical advantage in whatever the measure (PFS, OS).